| |
Total number
|
CR
|
PR
|
SD
|
PD
|
NE
|
ORR
|
DCR
|
|---|
|
1st-line treatment
|
|
All patients
|
50
|
1
|
4
|
12
|
27
|
6
|
10.0%
|
34.0%
|
|
Gemcitabine
|
24
|
0
|
1
|
5
|
15
|
3
|
4.2%
|
25.0%
|
|
S-1
|
12
|
0
|
0
|
5
|
6
|
1
|
0.0%
|
41.7%
|
|
Gemcitabine plus nab-paclitaxel
|
6
|
0
|
2
|
1
|
2
|
1
|
33.3%
|
50.0%
|
|
Gemcitabine plus S-1
|
2
|
0
|
0
|
0
|
2
|
0
| |
|
FOLFIRINOX
|
2
|
0
|
1
|
0
|
1
|
0
|
|
S-1 plus radiation
|
1
|
0
|
0
|
1
|
0
|
0
|
|
Paclitaxel
|
1
|
1
|
0
|
0
|
0
|
0
|
|
S-1 plus cisplatin
|
1
|
0
|
0
|
0
|
1
|
0
|
|
Gemcitabine plus radiation
|
1
|
0
|
0
|
0
|
0
|
1
|
|
2nd-line treatment
|
|
All patients
|
13
|
0
|
1
|
4
|
4
|
4
|
7.7%
|
38.5%
|
|
S-1
|
6
|
0
|
0
|
3
|
1
|
2
|
0.0%
|
50.0%
|
|
Gemcitabine
|
2
|
0
|
0
|
0
|
1
|
1
| |
|
Gemcitabine plus nab-paclitaxel
|
2
|
0
|
0
|
0
|
1
|
1
|
|
FOLFIRINOX
|
2
|
0
|
1
|
1
|
0
|
0
|
|
FOLFOX
|
1
|
0
|
0
|
0
|
1
|
0
|
|
3rd-line treatment
|
|
All patients
|
2
|
0
|
1
|
1
|
0
|
0
| |
|
Gemcitabine
|
1
|
0
|
0
|
1
|
0
|
0
|
|
Gemcitabine plus nab-paclitaxel
|
1
|
0
|
1
|
0
|
0
|
0
|
|
Cumulative total
|
|
All patients
|
65
|
1
|
6
|
17
|
31
|
10
|
10.8%
|
36.9%
|
|
Gemcitabine
|
27
|
0
|
1
|
6
|
16
|
4
|
3.7%
|
25.9%
|
|
S-1
|
18
|
0
|
0
|
8
|
7
|
3
|
0.0%
|
44.4%
|
|
Gemcitabine plus nab-paclitaxel
|
9
|
0
|
3
|
1
|
3
|
2
|
33.3%
|
44.4%
|
- CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, PFS progression-free survival, CI confidence interval, NR not reached
